Meyer WH - Search Results

1

Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children.

Furman WL, Stewart CF, Poquette CA, Pratt CB, Santana VM, Zamboni WC, Bowman LC, Ma MK, Hoffer FA, Meyer WH, Pappo AS, Walter AW, Houghton PJ. Furman WL, et al. Among authors: meyer wh. J Clin Oncol. 1999 Jun;17(6):1815-24. doi: 10.1200/JCO.1999.17.6.1815. J Clin Oncol. 1999. PMID: 10561220 Clinical Trial.

2

Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group.

Pappo AS, Lyden E, Breitfeld P, Donaldson SS, Wiener E, Parham D, Crews KR, Houghton P, Meyer WH; Children's Oncology Group. Pappo AS, et al. Among authors: meyer wh. J Clin Oncol. 2007 Feb 1;25(4):362-9. doi: 10.1200/JCO.2006.07.1720. J Clin Oncol. 2007. PMID: 17264331 Clinical Trial.

3

Phase I study of combination topotecan and carboplatin in pediatric solid tumors.

Athale UH, Stewart C, Kuttesch JF, Moghrabi A, Meyer W, Pratt C, Gajjar A, Heideman RL. Athale UH, et al. J Clin Oncol. 2002 Jan 1;20(1):88-95. doi: 10.1200/JCO.2002.20.1.88. J Clin Oncol. 2002. PMID: 11773158 Clinical Trial.

4

Ifosfamide plus etoposide in newly diagnosed Ewing's sarcoma of bone.

Meyer WH, Kun L, Marina N, Roberson P, Parham D, Rao B, Fletcher B, Pratt CB. Meyer WH, et al. J Clin Oncol. 1992 Nov;10(11):1737-42. doi: 10.1200/JCO.1992.10.11.1737. J Clin Oncol. 1992. PMID: 1403056

5

Phase I study of flavone acetic acid (NSC 347512, LM975) in patients with pediatric malignant solid tumors.

Pratt CB, Relling MV, Meyer WH, Douglass EC, Kellie SJ, Avery L. Pratt CB, et al. Among authors: meyer wh. Am J Clin Oncol. 1991 Dec;14(6):483-6. doi: 10.1097/00000421-199112000-00005. Am J Clin Oncol. 1991. PMID: 1957836 Clinical Trial.

6

Ifosfamide neurotoxicity is related to previous cisplatin treatment for pediatric solid tumors.

Pratt CB, Goren MP, Meyer WH, Singh B, Dodge RK. Pratt CB, et al. Among authors: meyer wh. J Clin Oncol. 1990 Aug;8(8):1399-401. doi: 10.1200/JCO.1990.8.8.1399. J Clin Oncol. 1990. PMID: 2380760

7

A phase I study of sulofenur in refractory pediatric malignant solid tumors.

Pratt CB, Bowman LC, Marina N, Pappo A, Avery L, Luo X, Meyer WH. Pratt CB, et al. Among authors: meyer wh. Invest New Drugs. 1995;13(1):63-6. doi: 10.1007/BF02614222. Invest New Drugs. 1995. PMID: 7499110 Clinical Trial.

8

Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in treatment of newly diagnosed pediatric solid tumors.

Marina NM, Rodman JH, Murry DJ, Shema SJ, Bowman LC, Jones DP, Furman W, Meyer WH, Pratt CB. Marina NM, et al. Among authors: meyer wh. J Natl Cancer Inst. 1994 Apr 6;86(7):544-8. doi: 10.1093/jnci/86.7.544. J Natl Cancer Inst. 1994. PMID: 8133538 Clinical Trial.

9

P-glycoprotein expression at diagnosis may not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma.

Kuttesch JF, Parham DM, Luo X, Meyer WH, Bowman L, Shapiro DN, Pappo AS, Crist WM, Beck WT, Houghton PJ. Kuttesch JF, et al. Among authors: meyer wh. J Clin Oncol. 1996 Mar;14(3):886-900. doi: 10.1200/JCO.1996.14.3.886. J Clin Oncol. 1996. PMID: 8622037

10

Topoisomerase I interactive drugs in children with cancer.

Stewart CF, Zamboni WC, Crom WR, Gajjar A, Heideman RL, Furman WL, Meyer WH, Houghton PJ, Pratt CB. Stewart CF, et al. Among authors: meyer wh. Invest New Drugs. 1996;14(1):37-47. doi: 10.1007/BF00173681. Invest New Drugs. 1996. PMID: 8880392 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

211 results

Search Page